Tahoe and Alloy to advance ADCs in joint venture

Privately-held US firms Tahoe Therapeutics and Alloy Therapeutics are to form a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for hard-to-treat cancers.

The joint venture will advance two ADC programs directed at novel tumor targets discovered by Tahoe using its proprietary Mosaic platform and large-scale, perturbative single-cell datasets. 

This collaboration is described as a strong strategic fit between Tahoe’s ability to identify high-confidence, tumor-selective targets using its AI-powered virtual cell models, and Alloy’s end-to-end capabilities in biologic drug engineering, ADC design, and company creation through its venture studio 82VS.